VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Overview of attention for article published in New England Journal of Medicine, October 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

news: 14 news outlets
blogs: 1 blog
policy: 1 policy source

twitter: 160 X users
patent: 1 patent
facebook: 2 Facebook pages

Citations

dimensions_citation: 285 Dimensions

Readers on

mendeley: 278 Mendeley

Summary News Blogs Policy documents X Patents Facebook Dimensions citations

So far, Altmetric has seen 1 blog post.

VX-659, Bamocaftor potassium

New Drug Approvals, 02 May 2019

VX-659, BAMOCAFTOR N-(Benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrol…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.